The recent analysis in JAMA focused on serious stomach disorders and GLP-1 agonists.

Researchers in Canada compared safety outcomes for GLP-1 agonists and bupropion-naltrexone, an older class of weight-loss medication. The retrospective analysis included 4144 people with obesity who were prescribed liraglutide, 613 prescribed semaglutide, and 654 prescribed the older treatment. People with a diabetes code in their health record were excluded from the study.

The GLP-1 group had a 9 times greater risk of pancreatitis, a 4 times greater risk of bowel obstruction, and a more than 3 times greater risk of gastroparesis, which causes stomach paralysis. The absolute risks in the GLP-1 group, however, were all about 1% or less per year of GLP-1 use. And semaglutide and liraglutide were not associated with biliary disease, which affects the gallbladder and bile production.

As Semaglutide’s Popularity Soars, Rare but Serious Adverse Effects Are Emerging — https://jamanetwork.com/journals/jama/fullarticle/2812192

Sorry, but as a reasonably normal human who lost >200 pounds without surgery or drugs I just don’t get it. We all want the easy way out I guess.